Dronabinol as an Adjunct for Reducing Pain
NCT06454669
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This exploratory, proof-of-concept study is a double-blind (participants and investigators will be blinded), placebo-controlled, randomized, two-arm clinical trial of Marinol [dronabinol, synthetic Δ9-tetrahydrocannabinol (THC)] for chronic low back pain (cLBP) with a 2:1 allocation ratio. Up to 75 subjects will be enrolled in this pilot study and randomized to receive doses of THC (up to 30 mg/day), orally, over 8 weeks. This study will be conducted at a single site; it does not include any stratifications, and there is no interim analysis planned.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Low Back Pain
- Chronic Pain
- Back Injuries
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 to 64 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Christopher D. Verrico
- Last updated on ClinicalTrials.gov
- May 18, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Texas · 1
- Michael E Debakey VA Medical Center · Houston, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.